At the news
? NEUTRALIMPACT 3/10 8-K filed Aug 12, 2026 at 08:18 ET
Madrigal Pharmaceuticals appointed John C. Reed, M.D., Ph.D., a top R&D executive from Johnson & Johnson, to its Board of Directors, expanding the board from eight to nine members. This is a routine governance move that adds significant scientific and industry expertise but provides no new financial data or strategic catalysts for the stock.
- Board expanded from 8 to 9 members with the appointment of John C. Reed, M.D., Ph.D.
- Dr. Reed is Executive Vice President, Innovative Medicine, R&D at Johnson & Johnson and a member of its Executive Committee.
- Dr. Reed will receive an annual cash retainer of $50,000, a $10,000 committee fee, and an initial equity grant valued at $675,000 (50% options, 50% RSUs).
- Dr. Reed was appointed to the Science and Technology Committee.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access